This observation aligns with a previous study conducted in HBsAg−/anti-HBc+ patients with rheumatoid arthritis, where the median interval from the initiation of immunosuppressants or bDMARDs to HBsAg seroreversion was 131 months (range, 20–196) and 90 months (range, 10–174), respectively [18]. The gene discussed is KRT88P; the disease is rheumatoid arthritis.